ArticleMolecular and clinical oncology2014

Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer.

Michio Kimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.